Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $2.41.

  • Harvard Bioscience's Debt to Equity rose 31660.71% to $2.41 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.41, marking a year-over-year increase of 31660.71%. This contributed to the annual value of $0.58 for FY2024, which is 1660.79% up from last year.
  • As of Q3 2025, Harvard Bioscience's Debt to Equity stood at $2.41, which was up 31660.71% from $2.22 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Debt to Equity registered a high of $2.42 during Q1 2025, and its lowest value of $0.5 during Q4 2023.
  • Over the past 5 years, Harvard Bioscience's median Debt to Equity value was $0.58 (recorded in 2024), while the average stood at $0.86.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 2378.32% in 2023, then skyrocketed by 36838.2% in 2025.
  • Over the past 5 years, Harvard Bioscience's Debt to Equity (Quarter) stood at $0.58 in 2021, then rose by 11.88% to $0.65 in 2022, then fell by 22.83% to $0.5 in 2023, then increased by 16.61% to $0.58 in 2024, then skyrocketed by 313.83% to $2.41 in 2025.
  • Its Debt to Equity was $2.41 in Q3 2025, compared to $2.22 in Q2 2025 and $2.42 in Q1 2025.